{"entity":{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","aka":[],"tldr":"AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.","summary":"Iambic Therapeutics, based in San Diego, has AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2 and CDK4 inhibitor. IAM1363, a brain-penetrant HER2 inhibitor, and IAM-H1 entered phase 1 between 2024 and 2025, and its NeuralPLexer models predict structure and binding. OnCo links it to HER2 as a target and to AI-driven drug and target discovery. Whether a brain-penetrant HER2 inhibitor can treat brain metastases better than existing HER2 drugs is the clinical question that matters most. The HER2 target page carries the competitive field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.iambic.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.iambic.ai","investors":[],"funding":[]},"route":"/companies/iambic-therapeutics/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"}]}}